Clinical trial Recruiting at 1 site Observational Ages 30 to 80

Observational study on α-synucleinopathy

Official title: A Registered Observational Cohort Study on α-Synucleinopathy

Run by Fujian Medical University Union Hospital · NCT05527067 · Data updated 2026-11-12

This study is trying to learn more about diseases like Parkinson's and dementia by collecting information over time to help doctors understand how these conditions change and progress.

Quick facts

Study typeObservational
Ages30 Years to 80 Years
SexAll
Enrollment500 (estimated)
SponsorFujian Medical University Union Hospital
Academic / other
Locations1 site (Fuzhou, Fujian)
StatusRecruiting
StartedSeptember 1, 2021
Main results expectedJune 2030
Study endsJune 2030
Registry record updatedMarch 23, 2023
Trial IDNCT05527067 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals with a clinical diagnosis of primary α-synucleinopathy and unrelated healthy controls.

Probably not a fit

Patients with secondary α-synucleinopathy or other neurological disorders, as well as pregnant or lactating women, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on α-synucleinopathy, a group of neurodegenerative diseases that includes Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies. It aims to collect data to enhance understanding of the natural history and progression of these conditions, utilizing multi-omics datasets. Data will be gathered both retrospectively at the time of research entry and prospectively during follow-up visits to aid healthcare providers in making informed medical decisions.

Why it matters

Potential benefit: If successful, this study could provide valuable insights that improve diagnosis and treatment strategies for patients with α-synucleinopathy.

How similar studies have gone: While this study is observational, similar studies have shown promise in understanding neurodegenerative diseases, suggesting potential for valuable findings.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participants with a clinical diagnosis of primary α-synucleinopathy
* Unrelated healthy controls

Exclusion Criteria:

* Patients with secondary α-synucleinopathy that cannot be excluded.
* Patients with other neurological disorders.
* Pregnant or lactating women.

Where it's running

  • Fujian Medical University Union Hospital
    Fuzhou, Fujian, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.